ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0674

Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies

Vincent Tran, Amy Schmitt and Shanthini Kasturi, Tufts Medical Center, Boston, MA

Meeting: ACR Convergence 2022

Keywords: antiphospholipid syndrome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Thrombosis and thrombocytopenia are defining characteristics of antiphospholipid syndrome (APS), but can also be seen in heparin-induced thrombocytopenia (HIT). Hospitalized patients with APS are often tested for HIT, but the prevalence of HIT in this population is unclear. Our study investigated the prevalence of HIT among high risk inpatients with APS or systemic lupus erythematosus (SLE) with antiphospholipid antibodies (aPL).

Methods: This was a retrospective cohort study of hospitalized adults meeting classification criteria for APS or SLE with aPL who were evaluated for HIT with anti-platelet factor 4 (PF4) antibodies or serotonin release assay (SRA). Patients were screened via the electronic medical record using International Classification of Diseases (ICD) codes. Of 33 patients identified in screening, 23 met study inclusion criteria (Table 1). Eighteen met 2019 American College of Rheumatology classification criteria for SLE, 11 met Sapporo classification criteria for APS, and 6 met both SLE and APS criteria. Demographics, clinical characteristics (reason for hospitalization, APS and SLE criteria, 4T score, anticoagulation status), and laboratory results (platelets, anti-PF4 antibodies, SRA) were extracted and clinical diagnosis of HIT was assessed using a positive SRA test.

Results: Of the 23 patients who met inclusion criteria, fourteen patients (61%) had a low probability 4T score, 9 (39%) with intermediate probability, and 0 with high probability. Of the 23 patients in whom PF4 antibodies were evaluated, only one patient (4%) tested positive. SRA was tested in a total of 4 patients (17%), including this patient, and was negative in all cases.

Conclusion: Among 23 inpatients with APS or SLE with aPL who were tested for HIT with anti-PF4 antibodies or SRA at a single tertiary care medical center, not one ultimately met clinical criteria for HIT. A majority of patients in this cohort had a 4T score that was low probability for a diagnosis of HIT, but were still tested for anti-PF4 antibodies. Our study suggests that the clinical syndrome of HIT is rare among hospitalized patients with APS or SLE with aPL and that anti-PF4 antibodies are often inappropriately tested for in this population.

Supporting image 1


Disclosures: V. Tran, None; A. Schmitt, None; S. Kasturi, GlaxoSmithKlein(GSK).

To cite this abstract in AMA style:

Tran V, Schmitt A, Kasturi S. Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-heparin-induced-thrombocytopenia-in-hospitalized-patients-with-antiphospholipid-syndrome-or-systemic-lupus-erythematosus-with-antiphospholipid-antibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-heparin-induced-thrombocytopenia-in-hospitalized-patients-with-antiphospholipid-syndrome-or-systemic-lupus-erythematosus-with-antiphospholipid-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology